Venus Remedies (VENUSREM) | Stock Overview & Key Data
Venus Remedies Performance Comparison
Stock Range
Today's Range
Low: ₹464.40
High: ₹483.20
on August 18, 2025
52 Week Range
Low: ₹270.25
High: ₹567.80
on January 28, 2025
on July 18, 2025
All-Time High: ₹639.00 on August 9, 2021
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR6.3B
EPS
40.17
P/E Ratio (TTM)
11.79
Forward P/E
N/A
P/B Ratio
1.13
PEG Ratio
0.02
Div. Yield
N/A
ROE
8.08%
Beta
0.443
Debt to Equity
0.30
Financial Highlights
Profitability
Gross Margin
43.78%
Operating Margin
2.97%
Profit Margin
8.00%
Returns and Earnings
Return on Assets (TTM)
6.33%
Return on Equity (TTM)
8.08%
EBITDA
INR888.0M
Net Income (TTM)
INR536.9M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR502.11
Quarterly Revenue Growth (YoY)
21.40%
Quarterly Earnings Growth (YoY)
686.90%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Venus Remedies VENUSREM | 6.33B Small-cap | -3.34% | -0.85% | 49.66% | 49.12% | 48.81% | 42.55% | 112.02% | 313.39% |
| Sun Pharmaceutical SUNPHARMA | 3.94T Large-cap | 2.69% | -2.45% | -3.91% | -3.48% | -13.15% | -5.82% | 82.10% | 208.33% |
| Divi's Laboratories DIVISLAB | 1.63T Large-cap | 0.02% | -9.53% | -1.34% | 4.94% | 0.98% | 32.34% | 65.91% | 88.85% |
| Sun Pharma Advanced SPARC | 45.51B Small-cap | -3.92% | -13.01% | -6.93% | -0.76% | -30.12% | -34.25% | -41.92% | -22.97% |
| Aarti Drugs AARTIDRUGS | 44.42B Small-cap | -3.86% | 1.23% | 5.23% | 18.26% | 6.84% | -2.04% | 8.97% | -37.88% |
| Sequent Scientific SEQUENT | 43.92B Small-cap | 0.45% | -5.27% | 0.82% | 19.96% | -4.81% | 22.66% | 59.79% | 34.23% |
Ownership & Short Interest
Insider Ownership
50.10%
Institutional Ownership
1.10%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
11K
Average 90-Day Volume
32K
Venus Remedies Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Venus Remedies would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is VENUSREM's 52-week high and low?
- In the last 52 weeks, Venus Remedies reached a high of ₹567.80 (on July 18, 2025) and a low of ₹270.25 (on January 28, 2025).
- What is the market cap and P/E ratio for VENUSREM?
- Curious about Venus Remedies's size and valuation? Its market capitalization stands at 6.33B. When it comes to valuation, the P/E ratio (trailing twelve months) is 11.79, and the forward P/E (looking ahead) is N/A.
- Does VENUSREM pay dividends? If so, what's the yield?
- As for dividends, Venus Remedies isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Venus Remedies's main competitors or similar companies to consider before investing?
When looking at Venus Remedies, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.94T Healthcare Drug Manufacturers - Specialty & Generic -5.82% 82.10% Divi's Laboratories
DIVISLAB1.63T Healthcare Drug Manufacturers - Specialty & Generic 32.34% 65.91% Sun Pharma Advanced
SPARC45.51B Healthcare Drug Manufacturers - Specialty & Generic -34.25% -41.92% Aarti Drugs
AARTIDRUGS44.42B Healthcare Drug Manufacturers - Specialty & Generic -2.04% 8.97% Sequent Scientific
SEQUENT43.92B Healthcare Drug Manufacturers - Specialty & Generic 22.66% 59.79% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Venus Remedies Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Venus Remedies's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 8.08%, the Debt to Equity ratio from the most recent quarter is 0.30, and its Gross Profit Margin stands at 43.78%.
- What is the recent revenue and earnings growth for VENUSREM?
- Looking at Venus Remedies's growth, its revenue over the trailing twelve months (TTM) was INR7B. Compared to the same quarter last year (YoY), quarterly revenue grew by 21.40%, and quarterly earnings saw a YoY growth of 686.90%.
- How much of VENUSREM stock is held by insiders and institutions?
- Wondering who owns Venus Remedies stock? Company insiders (like executives and directors) hold about 50.10% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 1.10%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.